Prof. Pablo Fernandez-Penas of the University of Sydney was recently interviewed on 7News Australia as the University of Queensland and the Australian Cancer Research Foundation announced the official launch of the Australian Centre of Excellence in Melanoma Imaging and Diagnosis (ACEMID). Prof. Fernandez-Penas highlighted the VECTRA WB360 and explained how 15 WB360 systems will be installed as part of this initiative bringing together researchers from the University of Queensland, University of Sydney, and Monash University to study melanoma using the system’s advanced body mapping technology. Prof. Penas is hopeful that up to 15,000 Australians across the states of Queensland, New South Wales, and Victoria will take part in future screenings using the VECTRA WB360, enabling researchers to collect images and develop advanced algorithms to aide melanoma detection.
In the News
Canfield’s VECTRA WB360 whole-body imaging system was recently installed at the clinic of Dr. Gerd Kautz and Dr. Ingrid Kautz in Konz, Germany, becoming the first system installed in a German private practice. The 3D imaging system will assist Dr. Gerd Kautz, his wife Dr. Ingrid Kautz, and other staff members as they examine patients for the earliest signs of melanoma using the system’s advanced body mapping technology. The VECTRA WB360 captures patient images using 92 SLR-cameras flashing with polarized and cross-polarized lighting for an enhanced look at skin features. After the images are captured, clinicians can view the entire skin’s surface and analyze a 3D bodymap of the patient using Canfield’s AI-driven DermaGraphix software, as they screen for signs of melanoma and monitor changes over time. Starting in early October, staff members at the practice will use the system to examine individual lesions and monitor their patients for potential skin cancer. Their practice is now the fifth VECTRA WB360 installation in Germany, including installations at the University Hospital in Erlangen, University Hospital in Munich, University Hospital in Dresden, and the Technical University of Munich.
University of Queensland’s Prof. H Peter Soyer discusses Canfield’s VECTRA WB360 and its role in expanding Australian melanoma research with 10 New First. Researchers plan to create a database of over 100,000 clinically-accessible VECTRA WB360 patient images, enhancing melanoma screening, early diagnosis, and long-term skin surveillance. The system’s presence at multiple locations in Australia is possible as part of a AUS $10 million grant from the Australian Cancer Research Foundation, as they are using the DermaGraphix advanced body mapping technology to combat the nation’s high rate of melanoma. The VECTRA WB360 captures cross polarized and non-polarized images to create a precise 3D body map of the patient. This 3D body map provides clinicians and researchers the ability to identify changes in suspicious lesions on the surface of the skin over time.
Jack Arbiser, MD, PhD, principal investigator and professor of dermatology at Emory University School of Medicine, has identified a new compound as an effective treatment for rosacea. Canfield’s VISIA Skin Analysis was used in clinical trials to document decreases in redness and track responses to the novel topical treatment, ACU-D1 (Accuitis Inc.).
Canfield’s VECTRA WB360 3D whole body imaging system was recently installed at Vienna General Hospital (AKH) to assist researchers and clinicians as they capture and screen non-polarized and cross-polarized 3D patient images for signs of melanoma and other serious skin conditions. Prof. Kittler is a dermatologist and instructor at the Department of Dermatology at the Medical University of Vienna who specializes in digital dermoscopy. Prof. Kittler has also published several research articles on digital dermoscopy and the dermosopic follow up of melanocytic nevi, as well as contributing to research on patient image standardization. DermaGraphix’s automatic lesion change detection and DEXI explainable AI-driven dermoscopy image analysis tools will help Prof. Kittler and his colleagues screen patients and conduct advanced research on pigmented lesions more efficiently and effectively.
CBS News interviewed Dr. Allan Halpern, Chief of Dermatology at Memorial Sloan Kettering Cancer Center, about the VECTRA WB360’s advanced imaging technology and its role assisting doctors in detecting signs of melanoma. Dr. Halpern demonstrated how the system captures cross-polarized and non-polarized images using 92 cameras firing simultaneously, providing an accurate 3D representation of the patient’s skin. The VECTRA WB360 provides clinicians like Dr. Halpern a powerful tool to screen patients thoroughly, especially important now since so many have missed their normal appointments in the past year due to the pandemic. The Journal of American Academy of Dermatology reported as many as 19,600 melanomas may not have been diagnosed or treated in 2020. Dr. Halpern explained that he is leveraging technology like the WB360 to “help do a better job, to catch melanoma at the earliest possible stage while at the same time avoiding a lot of unnecessary biopsies.”
Canfield’s VECTRA WB360 3D whole-body imaging system has been assisting doctors and specialists at INOVA Melanoma and Skin Cancer Center as they screen patients for skin cancer and conduct melanoma research. Since its installation in February 2019, the WB360 has provided body mapping technology and advanced 3D research tools to INOVA’S team of board certified dermatologists, oncologists, surgeons and pathologists.The VECTRA WB360 enables INOVA’s clinicians, physicians, and researchers to provide an unparalleled level of care for their patients.
Canfield’s VECTRA® WB360 3D whole-body imaging system was recently installed at the Skin Cancer Unit at the Hospital Clinic de Barcelona. The whole-body imaging system will assist Prof. Josep Malvehy, Dr. Susana Puig, and their colleagues as they capture patient images and track pigmented lesions on the skin’s surface. Prof. Malvehy is the Director of the Clinic’s Skin Care Unit and a world-renowned leader in the research, diagnosis, and treatment of skin cancer. Dr. Susanna Puig is the Head of the Dermatology Service and an expert in the diagnosis and treatment of melanoma and other skin cancers, while also specializing in confocal microscopy. Both Prof. Malvehy and Dr. Susana Puig are responsible for the introduction and validation of numerous diagnostic techniques for skin cancer and have published more than 400 research articles on the subject in international journals. The newly installed VECTRA WB360 system will provide Prof. Malvehy and Dr. Puig advanced body mapping technology and information from patient images that can further their clinical research. This installation is the second VECTRA WB360 system in Spain, with the first installed in Madrid at Grupo de Dermatologia Pedro Jaen where it is currently being used by Prof. Salvador Gonzalez.
Australia’s Seven Network Sunrise morning show featured the VECTRA WB360® whole-body 3D imaging system as a “technological breakthrough” for melanoma surveillance. Hosts David Koch and Natalie Barr discuss the whole-body imaging system with Associate Prof. Victoria Mar of Monash University in Melbourne, where she explains how the system’s advanced body mapping technology assists doctors in making more accurate melanoma diagnoses. Prof. Mar also mentions the infrastructure grant from the Australian Cancer Research Foundation, where 15 VECTRA WB360 systems will be placed in clinics across Queensland, New South Wales, and Victoria. The systems set up in these states will be part of a larger telehealth network, enabling patients in remote areas to take part in a very thorough risk assessment study. Prof. Mar explains how the approach using the VECTRA WB360 will help researchers monitor melanoma on a long-term basis and will place an emphasis on reaching remote patients so they can receive the highest level of care.
Cutting edge technology is making whole body screening easier than ever for both doctors and patients. Canfield's VECTRA® WB360 3D whole-body imaging system provides doctors with the technology to examine their patients efficiently for signs of sun damage and melanoma, reducing unnecessary biopsies and procedures. Dr. Steven Q. Wang, director of Dermatologic Surgery and Dermatology at Memorial Sloan Kettering Cancer Center shared, “the benefit to the patient is you don’t have to get all those benign lesions taken out.”
